Anti-Tumor Activity of BDTX-1535, an Irreversible CNS Penetrant Inhibitor of Multiple EGFR **Extracellular Domain Alterations, in Preclinical Glioblastoma Models**

Matthew Lucas¹, Melinda Merchant¹, Matthew O'Connor¹, Sherri Smith¹, Anthony Trombino¹, Nigel Waters¹, Jonathan Ball², Alessandra Breschi², Katie Igartua², Martin Kang², Elizabeth Buck¹ ¹Black Diamond Therapeutics, Cambridge, MA and New York, NY; ²Tempus Labs, Chicago, IL Abstract: #66

Background

ENA 2022

EGFR alterations, including mutation and amplification, are very common in glioblastoma multiforme (GBM), impacting over 60k patients per year. No targeted therapy has been approved for GBM. The standard of care remains surgical resection followed by radiotherapy and adjuvant temozolomide.



Extracellular domain EGFR alterations found in GBM form covalent homodimers, impacting pharmacology and leading to potential for paradoxical activation by reversible inhibitors. We believe there are four criteria to an effective EGFR inhibitor in GBM:

- 1. Potent and selective against a broad family of extracellular domain alterations and amplification
- 2. High CNS penetration
- 3. Wild-type EGFR sparing
- 4. Irreversible binding to avoid paradoxical activation



Materials and Methods

BDTX-1535 preclinical exposure was evaluated in multiple species, PK and Kpuu values were calculated in plasma/ blood and brain/CSF. Antitumor activity was assessed across mouse PDX and allograft models. 2540 tumors were sequenced with the Tempus xT NGS assay. Mutational frequencies of oncogenic *EGFR* variants were assessed and relationship between treatment history and mutational frequency was analyzed.

Results.

BDTX-1535 is a CNS penetrant 4th generation irreversible EGFR MasterKey inhibitor targeting a family of EGFR alterations and amplification, while sparing wild type (WT) EGFR. BDTX-1535 was designed using the MAP Discovery Engine and targets the activated conformations used by oncogenic EGFR to drive tumor cell growth. BDTX-1535 meets all four criteria for an EGFR inhibitor to be effective in GBM.



4 Longitudinal sequencing of GBM patients demonstrates retention of oncogenic EGFR alterations during treatment





Oncogenic EGFR alterations in GBM are covalent homodimers unresponsive to currently available EGFR TKIs EGFR ECD mutants expressed in GBM form covalently activated **EGFR ECD mutants in GBM are** homodimers that can be paradoxically activated by reversible TKIs potently oncogenic Ba/F3 transformational potential of EGER alterations found in GBM PDX tumors expressing EGFRvIII 24 EGFR Mutations give rise to free cysteines at the ECD interface and can facilitate covalently linked oncogenic dimers BDTX-1535, an irreversible (covalent) EGFR inhibitor, achieves potent and sustained inhibition of EGFR alterations in GBM 6







Conclusions

BDTX-1535 is a 4th generation irreversible CNS penetrant MasterKey EGFR TKI targeting multiple oncogenic EGFR extracellular domain alterations and amplification in GBM patients and EGFR resistance mutations in NSCLC. Real world data demonstrate different EGFR alterations are frequently co-expressed and persist despite treatment. BDTX-1535 achieves potent anti-tumor activity against EGFR alterations and amplification across models including PDX and intracranial tumors. BDTX-1535 is currently in a phase I clinical study in patients with NSCLC and GBM harboring sensitive EGFR alterations (NCT05256290).

